Aduro’s three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies) have the potential to transform the ...
Advaxis’ Lm Technology uses live, attenuated bioengineered Listeria monocytogenes (Lm) bacteria to stimulate the immune system to view tumor cells as potentially ...
Agios works on cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic diseases and metabolic immuno-oncology.
Biologics. Amgen makes several therapeutic drugs that target serious disease. Many are derived from engineered monoclonal antibodies. Some target immune receptors.
Aminex Therapeutics, Inc., is a drug development company focused on discovery and development of a unique cancer drug therapy in the general category of cancer immunotherapies known as checkpoint ...
Apitope is a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases.
Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
A biopharmaceutical company that focuses on Cardiovascular and Metabolic diseases, Oncology, and Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal diseases, ...
Avalon GloboCare Corp. is a healthcare management provider and biotechnology developer, dedicated to integrating and managing global healthcare resources, empowering high-impact biomedical ...
A biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Develops next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), CAR T cell therapy, and TCR ...
The cancer immunotherapy research group is focused on the next generation of T cell engineering and creating a pipeline of T cell product candidates (CAR T cells) to treat a wide variety of liquid ...
Small Molecules, Biologics, Vaccines, The pipeline is comprised of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors.
Cellerant is developing novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics.
Compugen, via its wholly-owned subsidiary Compugen USA, Inc., is developing therapeutic antibodies against selected target proteins both for cancer immunotherapy and antibody-drug conjugate ...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies'
Committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Genenta is developing a gene transfer strategy into hematopoietic cells to target a specific anti-tumor protein. A disabled virus vector delivers the gene into the cells. A combination of ...
Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics
